Amylyx Pharmaceuticals In... (AMLX)
| Bid | 3.49 |
| Market Cap | 323.84M |
| Revenue (ttm) | 112.86M |
| Net Income (ttm) | -389.76M |
| EPS (ttm) | -4.43 |
| PE Ratio (ttm) | -0.83 |
| Forward PE | -1.62 |
| Analyst | Hold |
| Ask | 3.87 |
| Volume | 441,002 |
| Avg. Volume (20D) | 825,381 |
| Open | 3.80 |
| Previous Close | 3.87 |
| Day's Range | 3.56 - 3.83 |
| 52-Week Range | 1.57 - 7.27 |
| Beta | -0.51 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. ...
Analyst Forecast
According to 4 analyst ratings, the average rating for AMLX stock is "Hold." The 12-month stock price forecast is $7.5, which is an increase of 105.20% from the latest price.
Stock Forecasts
3 weeks ago · seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call TranscriptAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Josh Cohen - Co...
